Inventurus Knowledge Solutions Ltd
Complete IPO details, including price band, financials, subscription status, and key insights.
Participate in the Inventurus Knowledge Solutions Ltd IPO with full transparency. Review issue details, company fundamentals, and financial performance, and apply securely through Alice Blue.
IPO Snapshot
Key metrics and details at a glance.
Price Band
₹1,329
Per ShareLot Size
11 Shares
Minimum Investment
₹14,619
Issue Size
₹2,497.92 Cr
Face Value
₹1
Per ShareIPO Type
Book Building
Retail Quota
0%
QIB Quota
75%
NII Quota
15%
IPO Timeline
Important dates for your applying strategy.
Subscription Status
Live demand across investor categories.
Track real-time subscription levels:
*Real-time data subject to exchange updates
Inventurus Knowledge Solutions Ltd
Business model, operations, and market positioning.
Promoter Holding (Pre-Issue)
69.73%
Promoter Holding (Post-Issue)
65.81%
Issue Type
Book Building
ISIN
INE115Q01022
About the Company
We are a technology-enabled healthcare solutions provider and offer a care enablement platform assisting physician enterprises in the US, Canada and Australia, with a focus on the US markets. We offer a comprehensive platform that enables healthcare enterprises across outpatient and inpatient care. Our offerings include, Revenue Optimization Solutions, that enable healthcare organizations to generate, capture and optimize their revenue, improve operational efficiencies, and increase enterprise value through a cost-optimized, globalized, technologyenabled offering with on-demand scalability. Our Revenue Optimization Solutions are offered in the Pre-Visit Stage and include patient scheduling services and IKS EVE, at the Peri-Visit Stage and include clinical coding solutions and referral order management, at the Post Visit Stage that include Billing, Payment Posting, Denial Management, and Account Receivables Follow Up, IKS Optimix and at the In-Acute Settings Stage. We provide Clinical Support Solutions at each stage that include IKS Scribble, IKS Stacks, IKS AssuRx and IKS Migrate. In addition, we also provide clinical chart review and Hierarchical Condition Codes ("HCC") coding solutions which cater to our Value Based Care (VBC) portfolio. Our Unifying Data Platform solution enables healthcare organizations to ingest, aggregate, normalize, sort and clean clinical, financial and administrative data for a provider enterprise into a single enterprise data warehouse. We generate revenue from the sale of our services and offerings to clients. As of September 30, 2024, we served 778 US-based healthcare organizations. As of September 30, 2024.
Industry Overview
As per the Zinnov Report, the outsourced services market in the technology -enabled healthcare provider space is growing rapidly as providers seek to boost efficiency and streamline operations. By leveraging technologyenabled service providers to handle workflows like billing, revenue cycle management, patient engagement, and data analytics, healthcare organizations can focus on core patient care activities and achieve higher quality care while maintaining operational excellence.
Company History
Our Company was incorporated as "Inventurus Knowledge Solutions Private Limited" under the Companies Act, 1956 at Goa, pursuant to a certificate of incorporation dated September 5, 2006, issued by the Registrar of Companies, Goa, Daman and Diu at Goa. The registered office of our Company was shifted from Panduronga Timblo Industries, Akash Bhavan, 2nd Floor, Opp. Canara Bank, Panjim, Goa, India to Building No. 5 & 6, Unit No. 801, 8th Floor, Mindspace SEZ, Thane Belapur Road, Airoli, Navi Mumbai, Thane, Maharashtra, India - 400 708, with effect from January 1, 2020. On the conversion of our Company to a public limited company, pursuant to a resolution passed by Board on October 14, 2022 and our Shareholders on October 17, 2022, the name of our Company was changed to "Inventurus Knowledge Solutions Limited", consequent to which a fresh certificate of incorporation dated November 4, 2022 was issued by the Registrar of Companies, Maharashtra at Mumbai ("RoC").
Growth Strategy
- Maximise revenue from existing clients through a "land and expand" approach.
- Focus on large healthcare organizations.
- Move from a "human-led tech-enabled" model to a "tech-led human-enabled" model.
- Bundling our solutions for greater value-add.
- Leverage automation and Generative Artificial Intelligence (AI) to aid our operations.
- Partner with innovative clients for product development and innovation.
- Develop solutions to address the needs of entities moving to "Value-Based Care".
Financial Performance
Revenue, profit after tax and total assets across the last 3 reported financial years.
Revenue
Amount in ₹ crore
Profit After Tax (PAT)
Amount in ₹ crore
Total Assets
Amount in ₹ crore
Figures in ₹ crore, on a consolidated basis, as reported for FY24 to FY26.
Objects of the Issue
How the company plans to utilize IPO proceeds.
Use of Proceeds
The funds raised through this IPO will be used for:
Initial public offering of 18,795,510 equity shares of face value of Re. 1 each ("Equity Shares") of Inventurus Knowledge Solutions Limited ("The Company" or the "Issuer") for cash at a price of Rs. 1,329 per equity share (including a premium of Rs. 1,328) ("Offer Price") aggregating to Rs. 2497.92 crores, through an offer for sale of 18,795,510^equity shares of face value Re. 1 aggregating to Rs. 2497.92 crores, comprising 1,119,300^ equity shares of face value Re. 1 by Aryaman Jhunjhunwala Discretionary trust aggregating to Rs. 148.76 crores, 1,119,300 equityshares of face value Re. 1 by Aryavir Jhunjhunwala discretionary trust aggregating to Rs. 148.76 crores, 1,119,300 equity shares of face value Re. 1 by Nishtha Hunjhunwala discretionary trust aggregating to Rs. 148.76 crores ("Promoter Selling Shareholders"), 3,376,311 equity shares of face value Re. 1 by Ashra Family trust aggregating to Rs. 448.71 crores, 26,513^ equity shares of face value Re. 1 by Rajeshkumar Radheshyam Jhunjhunwala aggregating to Rs. 3.52 crores, ("Promoter Group Selling Shareholders"), 98,250 equityshares of face value Re. 1 by Adheet sharad gogate aggregating to Rs. 13.06 crores, 139,042 equity shares of face value Re. 1 by Ajay Madhavan Madatiparambil aggregating to Rs. 18.48 crores, 72,051 equity shares of face value Re. 1 by Ajit Rajagopal Menon aggregating to Rs. 9.58 crores, 104,281 equity shares of face value Re. 1 by Alan Muney aggregating to Rs. 13.86 crores, 69,521 equity shares of face value Re. 1 by Ankur Chugh aggregating to Rs. 9.24 crores, 323,572 equity shares of face value Re. 1 by Anurag Shiamsunderlal Sharma aggregating to Rs. 43.00 crores, 49,126 equity shares of face value Re. 1 by Arindrajit Datta aggregating to Rs. 6.53^ crores, 83,425 equity shares of face value Re. 1 by Ashit Kalra aggregating to Rs. 11.09 crores, 676,549 equity shares of face value Re. 1 by Berjis Minoo Desai aggregating to Rs. 89.91 crores, 5,297 equity shares of face value Re. 1 by Charles Edward Brown aggregating to Rs. 0.70 crores, 101,799 equity shares of face value Re. 1 by Christopher J Sclafani aggregating to Rs. 13.53 crores, 47,035 equity shares of face value Re. 1 by clarence carleton king ii aggregating to Rs. 6.25 crores, 33,406 equity shares of face value Re. 1 by Gaurav Jain aggregating to Rs. 4.44 crores, 1,251,378 equity shares of face value Re. 1 by Gautam Char aggregating to Rs. 166.31 crores, 1,141,001 equity shares of face value Re. 1 by Jeffrey Philip Freimark aggregating to Rs. 151.64 crores, 86,901 equity shares of face value Re. 1 by John Benardello aggregating to Rs. 11.55 crores, 3,041,812 equity shares of face value Re. 1 by Joseph Benardello aggregating to Rs. 404.26 crores, 232,341 equity shares of face value Re. 1 by K C Nishil Kumar aggregating to Rs. 30.88 crores, 49,126 equity shares of face value Re. 1 by Kareen Ribeiro Majmudar aggregating to Rs. 6.53 crores, 266,781 equity shares of face value Re. 1 by Katherine Nicole Davis aggregating to Rs. 35.46 crores, 130,594 equity shares of face value Re. 1 by Madathiparambil Krishnan Madhavan aggregating to Rs. 17.36 crores, 55,617 equity shares of face value Re. 1 by Manish Gupta aggregating to Rs. 35.46 crores, 166,850 equity shares of face value Re. 1 by Manu Mahmud Parpia (jointly held with lynn Manu Parpia) aggregating to Rs. 22.17 crores, 61,290 equity shares of face value Re. 1 by Mayur Pravinkant Sanghvi aggregating to Rs. 8.15^ crores, 219,170 equity shares of face value Re. 1 by Mitul dipak Thakker aggregating to Rs. 29.13 crores, 3,000 equity shares of face value Re. 1 by Nikhil Sharma aggregating to Rs. 0.40 crores, 1,251,378 equity shares of face value Re. 1 by Parminder Bolina aggregating to Rs. 166.31 crores, 257,873 equity shares of face value Re. 1 by Patrick Burton Cline aggregating to Rs. 34.27 crores, 47,815 equity shares of face value Re. 1 by Sanjiv Bhupendra Gandhi aggregating to Rs. 6.36 crores, 652,008 equity shares of face value Re. 1 by Scott D Hayworth aggregating to Rs. 86.65 crores, 994,233 equity shares of face value Re. 1 by Shane Hsuing Peng aggregating to Rs. 132.13 crores, 15,000 equity shares of face value Re. 1 by Srikanth Vadakapurapu aggregating to Rs. 1.99 crores, 208,563 equity shares of face value Re. 1 by Nikrishnan parthasarathy aggregating to Rs. 27.72 crores, 34,760 equity shares of face value Re. 1 by Varadharajan Ramasamy aggregating to Rs. 4.62 crores and 63,941 equity shares of face value Re. 1 by Vikram Jit Singh Chhatwal aggregating to Rs. 8.50 crores, (the "Individual Selling Shareholders", together with the promoter selling shareholders and promoter group selling shareholders, the "Selling Shareholders") (the "Offer for Sale" or the "Offer"). The offer included a reservation of 65,000 equity shares of face value Re. 1 each, aggregating to Rs. 8.64 crores, for subscription by eligible employees not exceeding 5% of its post-offer paid-up equity share capital (the "Employee Reservation Portion"). The offer less the employee reservation portion is hereinafter referred to as the "Net Offer". The offer and the net offer constituted 10.95 % and 10.92 %, respectively, of the fully diluted post-offer paid-up equity share capital of the company.
*Subject to approvals and market conditions.
Strengths & Risks
Key competitive advantages and factors to consider before investing.
- Comprehensive one-stop platform with diversified offerings across the outpatient and inpatient care value chain serving key stakeholders such as patients, physicians, nurses and healthcare organizations.
- Leveraging digital evolution, transformation and automation technologies to create sustained value based on outcomes delivered.
- Strong brand driven by clinical thought leadership through IKS Advisory Board, a healthcare industry leadership forum, and partnerships with industry players and evident through multiple awards and recognitions.
- Marquee large enterprise clientele that include academic medical centres and healthcare systems, multispecialty and single-specialty medical groups, ancillary healthcare organizations, value enablers, and other outpatient healthcare delivery organizations and client stickiness reflected in revenues from repeat clients of over 98% in the last three Fiscals.
- Sustainable and scalable business model offering clients flexibility and cost-savings and high-touch engagement through access to project executive sponsors and leadership teams creating cross-selling opportunities.
- There have been certain FEMA related deficiencies in compliances in the past by the Company and some of its existing and erstwhile shareholders, with respect to issuance of securities of the Company, delays in relation to reporting requirements and transfer of securities of the Company. The company has filed compounding applications with the RBI in respect of such contraventions, which are currently pending. Consequently, its may be subject to regulatory actions and penalties/ compounding fees, as applicable.
- The company has outstanding litigation against it, an adverse outcome of which may adversely affect its business, reputation and results of operations.
- If the company fails to successfully develop and introduce new solutions based on artificial intelligence and machine learning technologies and features to existing solutions such as AI-powered speech-to-text solutions, its revenues, operating results and reputation could suffer.
- The healthcare industry is regulated and if the company fails to comply with applicable healthcare laws and government regulations, its could incur financial penalties, be required to make significant operational changes or experience adverse publicity, which could harm its business.
- Various challenges currently faced by the healthcare industry in the United States including the provision of quality healthcare in a competitive environment and managing costs at the same time and consolidation of healthcare organizations in the United States may adversely affect its business, results of operations and financial condition.